IBD Treatment Market to Hit US$ 39.5 Billion by 2031 | Exclusive Report by Growth Plus Reports

Newark, New Castle, USA, July 03, 2023 (GLOBE NEWSWIRE) — A recent report by Growth Plus Reports estimated the global IBD treatment market to be worth US$ 23.8 billion in 2022. From 2023 to 2031, market revenue is expected to grow at a CAGR of 5.8%, reaching US$ 39.5 billion. The most successful strategies, market trends, the competitive environment, significant drivers and opportunities, statistical data, market size, and revenue are all included in the report. 

Key Takeaways: 

• The increasing case of fecal incontinence is driving the market revenue growth. 
• The demand for IBD treatment is a result of increased investment in R&D. 
• The growing prevalence of Crohn’s disease and other rare diseases contributes to revenue growth. 

Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/ibd-ulcerative-colitis-and-crohns-disease-treatment-market/8516

                                                        IBD treatment market Scope

Market Drivers: 
The market revenue for therapies for inflammatory bowel illness is expected to rise as ulcerative colitis and Crohn’s disease becomes more common. Additionally, obesity, stress, and lifestyle changes may result in ulcerative colitis and Crohn’s disease, contributing to market revenue growth. 

Market Segmentation: 
Growth plus reports have analyzed the global IBD treatment market from perspectives such as drug class, distribution channel, and region. 

Drug Class Segmentation: 
Based on the drug class, the global IBD treatment market is segmented as TNF inhibitors, JAK inhibitors, aminosalicylates, integrin antagonists, corticosteroids, and others.

The TNF inhibitors segment accounts for the largest revenue share in the global IBD treatment market. The extended clinical remission, sparing of corticosteroids, attaining mucosal healing, and averting disease-related comorbidities are all factors that contribute to the substantial revenue share. Moreover, utilizing anti-TNF medicines improves outcomes for IBD patients significantly. 

Request for Customization – https://growthplusreports.com/inquiry/customization/ibd-ulcerative-colitis-and-crohns-disease-treatment-market/8516

Distribution Channel Segmentation: 
Based on the distribution channels, the global IBD treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The hospital pharmacies segment accounted for the largest revenue share in the global IBD treatment market. The rise in the revenue share is attributed to the benefits of the distribution of compounded medications. 

Regional Growth Dynamics: 
Based on the region, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America accounts for the largest revenue share in the global IBD treatment market. This large revenue share is attributed to drug discoveries, the rising prevalence of disease, and successful reimbursement policies in this region. 

Competitive Landscape:
The major market players operating in the global IBD treatment market include:

• Merck & Co., Inc.
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Eli Lilly and Company 
• AbbVie Inc. 
• Takeda Pharmaceutical Company Limited
• Biogen
• Novartis AG
• UCB S.A.
• CELLTRION INC.

The market is heavily consolidated, with several big companies holding a substantial chunk. Market leaders value their dominant position and have many biological drugs for treating ulcerative colitis and Crohn’s disease. The company has become a significant player on the international scene because of its effective penetration across important geographies. This dominance by top market players is reinforced by their recent product launches and mergers & acquisitions.

Recent Developments: 

• In December 2022, The U.S. Food and Drug Administration (FDA) accepted for evaluation a New Drug Application (NDA) for etrasimod for those with moderately to highly active ulcerative colitis, according to Pfizer Inc. (U.C.).

• In March 2022, RINVOQ, a Janus kinase inhibitor from AbbVie, Inc., was approved by the U.S. FDA for treating ulcerative colitis.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
   4. Reimbursement Scenario 
   5. Epidemiology and Patient Population (Forecast to 2031)
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL IBD TREATMENT MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
   1. TNF Inhibitors
   2. JAK Inhibitors
   3. Amino-salicylates
   4. Integrin Antagonists
   5. Corticosteroids
   6. Others
6. GLOBAL IBD TREATMENT MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies

IBD TREATMENT MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8516

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Combination Antihypertensives Market by Type (ACE Inhibitors with Calcium Channel blocking agents, ACE inhibitors with thiazides), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Hydatid Disease Treatment Market by Drug (Mebendazole, Albendazole), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

High-Grade Neuroendocrine Neoplasms Market by Drug Class (Platinum Coordination Complexes, Somatostatin Analogues), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Postoperative Pain Medication Market by Drug Class (NSAIDS, Opioids), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Mast Cell Stabilizers Market by Type (Mastocytosis, Seasonal Allergic Rhinitis, and Perennial Allergic Conjunctivitis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook and Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech:  https://growthplusmedtechroundup.com

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.